Evolving approaches in advanced gallbladder cancer with complete pathological response using chemo‑immunotherapy: A case report

Orlandi,Elena; Toscani,Ilaria; Trubini,Serena; Schena,Alberto; Palladino,Maria Angela; Anselmi,Elisa; Vecchia,Stefano; Romboli,Andrea; Giuffrida,Mario

doi:10.3892/ol.2024.14606

Evolving approaches in advanced gallbladder cancer with complete pathological response using chemo‑immunotherapy: A case report

Authors:
- Elena Orlandi
- Ilaria Toscani
- Serena Trubini
- Alberto Schena
- Maria Angela Palladino
- Elisa Anselmi
- Stefano Vecchia
- Andrea Romboli
- Mario Giuffrida
View Affiliations

Affiliations: Department of Oncology‑Hematology, Piacenza General Hospital, I‑29121 Piacenza, Italy, Department of Pharmacy, Piacenza General Hospital, I‑29121 Piacenza, Italy, Department of General Surgery, Piacenza General Hospital, I‑29121 Piacenza, Italy
Published online on: August 2, 2024 https://doi.org/10.3892/ol.2024.14606
Article Number: 473
Copyright: © Orlandi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The combination of chemotherapy and immunotherapy for metastatic cholangiocarcinoma (CCA) offers promising improvements in survival and response rates beyond traditional treatments. TOPAZ‑1 and KEYNOTE‑966 have demonstrated the efficacy of combining immunotherapy (durvalumab and pembrolizumab) with chemotherapy, even in gallbladder cancer (GBC), with a complete response rate of 2.7% in the TOPAZ‑1 trial. Advanced CCA treated with immunotherapy combinations has shown complete responses influenced by high programmed death‑ligand 1 (PD‑L1) or Epstein‑Barr virus expression. These responses were enhanced by combining radiotherapy with programmed cell death protein 1 (PD‑1) blockade. A 62‑year‑old man was diagnosed with unresectable GBC, distant lymphatic metastases, and local invasion of liver segments 4i and 5, the colonic hepatic flexure, the duodenal bulb, and the pancreatic head. Immunohistochemical examination revealed poorly differentiated squamous cell carcinoma, without expression of PD‑L1. Next generation sequencing revealed the mutation of ERBB2 R678Q and a microsatellite stable tumour. The patient started chemo‑immunotherapy with cisplatin‑gemcitabine plus durvalumab in June 2022. After eight cycles, a significant reduction in tumour volume and markers was reported, and therapy with durvalumab was maintained through November 2023. The subsequent computed tomography scans showed further reduction in the tumour volume, and surgical resection was performed. Histological examinations confirmed the absence of residual tumour or lymph node metastases. As of June 2024, the patient has shown no signs of disease recurrence. Several reports of conversion surgery in GBC exist, but data on pre‑surgical chemo‑immunotherapy are limited. Furthermore, a complete response without pathological confirmation in CCA and GBC raises several questions regarding the need for surgery after immunotherapy. Although effective disease control and tumour regression have been reported in advanced GBC with combined anti‑cytotoxic T‑lymphocyte associated protein 4 and anti‑PD‑1 agents and chemotherapy, further studies are needed to identify reliable predictive biomarkers due to unclear associations with PD‑L1 expression or tumour mutational burden. Overall, chemo‑immunotherapy has been effective in treating metastatic CCA, especially when tailored to specific molecular profiles. These treatments may lead to complete responses and novel strategies.

View Figures

View References

1	Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, D'Angelica M, Dematteo RP, Blumgart LH and O'Reilly EM: Gallbladder cancer (GBC): 10-Year experience at memorial sloan-kettering cancer centre (MSKCC). J Surg Oncol. 98:485–489. 2008. View Article : Google Scholar : PubMed/NCBI
2	Jin LX, Pitt SC, Hall BL and Pitt HA: Aggressive surgical management of gallbladder cancer: At what cost? Surgery. 154:266–273. 2013. View Article : Google Scholar : PubMed/NCBI
3	Valle J, Kelley R, Nervi B, Oh D and Zhu A: Biliary tract cancer. Lancet. 397:428–444. 2021. View Article : Google Scholar : PubMed/NCBI
4	Lo JH, Agarwal R, Goff LW and Heumann TR: Immunotherapy in biliary tract cancers: Current standard-of-care and emerging strategies. Cancers (Basel). 15:33122023. View Article : Google Scholar : PubMed/NCBI
5	Oh DY, Lee KH, Lee DW, Kim TY and Bang YJ: Durvalumab plus gemcitabine and cisplatin for advanced biliary tract cancers: A phase III study (TOPAZ-1). Cancer Discov. 12:678–688. 2022.
6	Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, et al: Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 401:1853–1865. 2023. View Article : Google Scholar : PubMed/NCBI
7	Zhang Z, Wang G, Du L, Zhao J, Pan L, Zhang G, Wang F and Liu R: Case report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma. Front Immunol. 14:11244822023. View Article : Google Scholar : PubMed/NCBI
8	Wang L, Zhang J, Ban X, Li Z and Fang Y: A novel mixture of dose-fractioned radiation and PD-1 inhibitor produces significant tumor control in a patient with advanced intrahepatic cholangiocarcinoma: A case report. J Med Case Rep. 17:892023.
9	Liao W, Huang J, Liang Y, Zhou F and Pan Z: PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. J Clin Oncol. 41:337–344. 2023.
10	He H, Zhao H, Chen L, Zhang Y and Yu H: Long survival of immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma with high PD-L1 expression: A case report. Cancer Biol Ther. 23:1–6. 2022.PubMed/NCBI
11	Balakrishnan A, Barmpounakis P, Demiris N, Jah A, Spiers HVM, Talukder S, Martin JL, Gibbs P, Harper SJF, Huguet EL, et al: Surgical outcomes of gallbladder cancer: The OMEGA retrospective, multicentre, international cohort study. EClinicalMedicine. 59:1019512023. View Article : Google Scholar : PubMed/NCBI
12	Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
13	André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F and Scheithauer W: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: A phase II study. Br J Cancer. 99:862–867. 2008. View Article : Google Scholar : PubMed/NCBI
14	Hakeem AR, Papoulas M and Menon KV: The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer-A systematic review. Eur J Surg Oncol. 45:83–91. 2019. View Article : Google Scholar : PubMed/NCBI
15	Toyoda J, Sahara K, Takahashi T, Miyake K, Yabushita Y, Sawada Y, Homma Y, Matsuyama R, Endo I and Pawlik TM: Neoadjuvant therapy for extrahepatic biliary tract cancer: A propensity score-matched survival analysis. J Clin Med. 12:26542023. View Article : Google Scholar : PubMed/NCBI
16	Miura Y, Ashida R, Sugiura T, Ohgi K, Yamada M, Otsuka S, Todaka A and Uesaka K: Pathological complete response achieved by gemcitabine plus cisplatin therapy for initially unresectable advanced gallbladder cancer: A case report. Surg Case Rep. 8:202022. View Article : Google Scholar : PubMed/NCBI
17	Satyananda V, Chouliaras K, Cherkassky L and Schwarz RE: A case from the future of HPB surgical oncology: Resection of biliary tract cancer after immunotherapy. J Surg Case Rep. 2021:rjab4142021. View Article : Google Scholar : PubMed/NCBI
18	Zhang S, Nie J, Tai S and Zheng T: PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer. BMJ Case Rep. 16:e2554032023. View Article : Google Scholar : PubMed/NCBI
19	Wang Q, Mu Y, Ji S, Liu Y, Lou Y, Wei S, Dong X and Zhang B: Case report: Complete pathological remission of human chorionic gonadotrophin-producing gallbladder carcinoma with multiple liver metastases after treatment with chemotherapy plus an immune checkpoint inhibitor. Front Immunol. 14:11735202023. View Article : Google Scholar : PubMed/NCBI
20	Leong EKF, Tan NCH, Pang NQ and Kow AWC: Case report: From palliative to potentially curative-the advent of immunotherapy providing hope to advanced gallbladder adenocarcinoma. Front Immunol. 15:13534302024. View Article : Google Scholar : PubMed/NCBI
21	Patel SP, Guadarrama E, Chae YK, Dennis MJ, Powers BC, Liao CY, Ferri WA Jr, George TJ, Sharon E, Ryan CW, et al: SWOG 1609 cohort 48: Anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer. Cancer. Feb 15–2024.(Epub ahead of print).
22	Tan S, Yu J, Huang Q, Zhou N and Gou H: PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series. Front Oncol. 12:10060752022. View Article : Google Scholar : PubMed/NCBI
23	Rao J, Xia J, Yang W, Wu C, Sha B, Zheng Q, Cheng F and Lu L: Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer: A case report. Ann Transl Med. 8:16092020. View Article : Google Scholar : PubMed/NCBI
24	Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, Fazio N and Valle JW: HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target? Cancer Metastasis Rev. 36:141–157. 2017. View Article : Google Scholar : PubMed/NCBI
25	Koido S, Kan S, Yoshida K, Yoshizaki S, Takakura K, Namiki Y, Tsukinaga S, Odahara S, Kajihara M, Okamoto M, et al: Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. Anticancer Res. 34:6353–6361. 2014.PubMed/NCBI
26	Davis AA and Patel VG: The role of PD-L1 expression as a predictive biomarker: An analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 7:2782019. View Article : Google Scholar : PubMed/NCBI
27	Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, Palma N, Morosini D, Miller VA, Yelensky R, et al: Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist. 20:7–12. 2015. View Article : Google Scholar : PubMed/NCBI